| Literature DB >> 26186370 |
Harin Rhee1, Keum Sook Jang2, Min Ji Shin1, Jang Won Lee1, Il Young Kim3, Sang Heon Song1, Dong Won Lee3, Soo Bong Lee3, Ihm Soo Kwak1, Eun Young Seong1.
Abstract
INTRODUCTION: Fluid overload is a well-known predictor of mortality in patients with acute kidney injury (AKI). Multifrequency bioimpedance analysis (MF-BIA) is a promising tool for quantifying volume status. However, few studies have analyzed the effect of MF-BIA-defined volume status on the mortality of critically ill patients with AKI. This retrospective medical research study aimed to investigate this issue.Entities:
Mesh:
Year: 2015 PMID: 26186370 PMCID: PMC4505923 DOI: 10.1371/journal.pone.0133199
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Summary of study flow.
Cause of CVVHDF initiation.
| Causes | % |
|---|---|
|
|
|
| Septic shock associated with AKI | 40.9(85/208) |
| Oliguric AKI other than sepsis | |
| Rhabdomyolysis | 9.6(20/208) |
| Tumorlysis syndrome | 7.2(15/208) |
| Ischemic ATN | 5.3(11/208) |
| Drug induced AKI | 2.9(6/208) |
| contrast induced nephropathy | 1.4(3/208) |
| Post renal AKI | 0.9(2/208) |
|
|
|
| Refractor heart failure | 10.6(22/208) |
| Acute coronary syndrome | 7.2(15/208) |
| Nephrotic syndrome | 1.4(3/208) |
|
|
|
| Acute brain injury | 4.3(9/208) |
| Generalized brain edema | 2.9(6/208) |
|
|
|
| Diabetic ketoacidosis | 1.4(3/208) |
| Alcoholic ketoacidosis | 1.4(3/208) |
|
|
|
| Ethylene glycol | 1.4(3/208) |
| Lithium | 0.9(2/208) |
Foot note: In most of the cases, the indications of initiating CVVHDF were more than one, and we described most potent indication among them. Oliguria is defined as urine output <0.5ml/kg/hr for ≥12 hours. Abbreviations: AKI, acute kidney injury; CVVHDF, continuous veno-venous hemodiafiltration.
Patient characteristics, biologic data and treatment according to the quartiles of TBW/H2.
| Total (N = 208) | 1st quartile (N = 52) | 2nd quartile (N = 52) | 3rd quartile (N = 52) | 4th quartile (N = 52) | P | |
|---|---|---|---|---|---|---|
|
| ||||||
| Age, year | 65.19±12.90 | 66.61±10.98 | 66.00±13.61 | 65.28±13.68 | 62.80±13.38 | 0.623 |
| Height,cm | 168.26±6.35 | 167.09±5.11 | 167.75±7.19 | 168.71±3.93 | 169.54±6.01 | 0.390 |
| Weight.kg | 64.17±10.54 | 55.81±8.58 | 60.75±8.61 | 67.47±7.39 | 72.98±8.99 | <0.001 |
| BMI.kg/m2 | 22.62±3.21 | 20.01±3.11 | 21.59±2.75 | 23.68±1.84 | 25.33±2.22 | <0.001 |
|
| ||||||
| MAP, mmHg | 79.50±16.71 | 81.44±15.31 | 77.43±14.34 | 81.95±19.05 | 77.32±18.01 | 0.515 |
| Vasopressor, % | 62.9 | 58.3 | 55.6 | 61.1 | 77.1 | 0.236 |
| SOFA score | 10.61±3.98 | 8.93±2.97 | 10.51±4.05 | 11.00±3.84 | 11.86±4.44 | 0.025 |
| APACHII score | 24.58±6.43 | 24.38±6.23 | 23.57±6.03 | 25.00±6.97 | 25.43±6.62 | 0.656 |
| SAPSII | 55.13±18.97 | 53.00±17.67 | 52.48±17.52 | 53.03±21.81 | 61.37±18.06 | 0.157 |
| Septic AKI, % | 40.0 | 45.7 | 48.6 | 31.4 | 34.3 | 0.377 |
| Initial ECW/TBW | 0.409±0.018 | 0.412±0.011 | 0.408±0.013 | 0.412±0.014 | 0.406±0.028 | 0.351 |
| TBW/H2,L/m2 | 14.12±2.22 | 11.33±0.87 | 13.39±0.48 | 14.91±0.38 | 16.94±1.32 | <0.001 |
| ECW/H2,L/m2 | 5.77±0.97 | 4.69±0.39 | 5.39±0.46 | 6.13±0.27 | 6.89±0.82 | <0.001 |
| ICW/H2,L/m2 | 8.36±1.35 | 6.65±0.54 | 7.99±0.46 | 8.78±0.30 | 10.05±0.81 | <0.001 |
| Phase angle,° | 3.97±2.41 | 3.13±2.44 | 3.99±1.28 | 4.25±3.08 | 4.49±2.38 | 0.094 |
|
| ||||||
| WBC,/uL | 14.42±9.60 | 13.31±8.11 | 14.06±8.43 | 16.91±13.27 | 13.54±7.78 | 0.391 |
| Hb, g/dL | 10.32±2.27 | 10.08±1.65 | 10.29±2.51 | 10.50±2.07 | 10.41±2.72 | 0.881 |
| TP, g/dL | 5.53±1.06 | 5.89±0.91 | 5.41±0.97 | 5.57±1.23 | 5.23±1.06 | 0.057 |
| Albumin,g/dL | 2.99±0.67 | 3.22±0.63 | 2.94±0.72 | 2.98±0.63 | 2.85±0.66 | 0.109 |
| pH, mmHg | 7.31±0.13 | 7.31±0.15 | 7.32±0.13 | 7.28±0.11 | 7.31±0.12 | 0.613 |
| BUN,mg/dL | 54.51±30.73 | 54.32±28.49 | 51.48±28.08 | 57.39±29.71 | 55.01±36.81 | 0.889 |
| Creatinine,mg/dL | 3.84±2.79 | 4.08±2.78 | 3.99±2.51 | 3.91±3.01 | 3.40±2.93 | 0.763 |
| Na,mmol/L | 137.52±7.28 | 136.73±7.34 | 136.63±6.41 | 138.37±6.83 | 138.42±8.47 | 0.595 |
| K, mmol/L | 4.50±1.08 | 4.62±0.98 | 4.32±1.09 | 4.50±1.17 | 4.59±1.12 | 0.657 |
| PT, INR | 1.56±0.56 | 1.48±0.39 | 1.50±0.49 | 1.63±0.67 | 1.63±0.64 | 0.598 |
|
| ||||||
| Initiation time, d | 1.38±3.06 | 1.50±3.70 | 1.09±1.98 | 1.22±3.43 | 1.77±2.92 | 0.821 |
| Actual dose, mL/kg/hr | 31.62±9.72 | 36.76±10.21 | 30.33±10.67 | 29.94±8.31 | 29.65±8.19 | 0.008 |
| CVVHDF duration, d | 5.21±3.06 | 4.58±3.52 | 6.19±5.57 | 4.22±4.10 | 5.80±2.03 | 0.593 |
| Total ICU stay, d | 18.29±27.48 | 18.50±29.33 | 19.93±29.09 | 10.25±8.69 | 24.42±35.63 | 0.227 |
Foot note: 1st quartile, TBW/H2<12.5 L/m2; 2nd quartile, 12.5 L/m2≤TBW/H2<14.2 L/m2; 3rd quartile, 14.2 L/m2≤TBW/H2<15.5 L/m2; 4th quartile, TBW/H2≥15.5 L/m2. Abbreviations: H, height; BMI, body mass index; MAP, mean arterial pressure; SOFA, sequential organ failure assessment; ECW, extracelluar water; TBW, total body water; ICW, intracellular water; BUN, blood urea nitrogen; TP, total protein; INR, international normalized ratio; CVVHDF, continuous veno-venous hemodiafiltration, ICU, intensive care unit.
Correlations of TBW/H2 with anthropometric and MF-BIA defined volume parameters in the critically ill male patients undergoing CVVHDF.
| R | P-value | |
|---|---|---|
| Age, yr | -0.073 | 0.385 |
| Height, cm | 0.147 | 0.078 |
| Weight, kg | 0.642 | <0.001 |
| BMI, kg/m2 | 0.656 | <0.001 |
| ECW/TBW | -0.052 | 0.552 |
| ECW/H2, L/m | 0.936 | <0.001 |
| ICW/H2, L/m | 0.968 | <0.001 |
| 50kHz BIVA parameters | ||
| Resistance/H, Ohm/m | -0.788 | <0.001 |
| Reactance/H, Ohm/m | -0.083 | 0.326 |
| Impedance/H vector, Ohm/m | -0.784 | <0.001 |
| Phase angle,° | 0.183 | 0.029 |
Abbreviations: BMI, body mass index; ECW, extracellular water; TBW, total body water; ICW, intracellular water; H2, height squared.
Fig 2Bioimpdedance vector analysis results of each TBW/H2 group displayed graphically comparing resistance/H (R/H) with reactance/H (Xc/H).
Male mean impedance/height vector from patients with acute kidney injury undergoing continuous veno-venous hemodiafiltration, plotted on the reference RXc graph [18] with 75th and 95th tolerance ellipses of the male healthy population. Abbreviations: Q1, 1st quartile, Q2, 2nd quartile, Q3, 3rd quartile and Q4, 4th quartile.
Fig 3In-hospital mortality showed the increasing pattern in accordance with increasing total body water/height2 quartiles in male patients with acute kidney injury undergoing continuous veno-venous hemodiafiltration (CVVHDF).
Total body water was measured at the time of CVVHDF initiation, with Inbody S20 (Biospace, Seoul, Korea).
Univariable analysis results predicting in hospital mortality in patients with acute kidney injury requiring CVVHDF therapy.
| In-hospital mortality | ||
|---|---|---|
|
|
| |
| Age, yr | 0.976(0.953–0.999) | 0.041 |
| Height, cm | 1.040(0.992–1.090) | 0.101 |
| Weight, kg | 1.302(1.004–1.061) | 0.025 |
| BMI, kg/m2 | 1.088(0.993–1.193) | 0.072 |
| Presence of sepsis | 1.495(0.838–2.668) | 0.174 |
| ECW/TBW | 31.86(0.000–61.03) | 0.722 |
| ECW/H2, L/m2 | 1.504(1.041–2.173) | 0.030 |
| ICW/H2, L/m2 | 1.404(1.079–1.827) | 0.011 |
| TBW/H2, L/m2 | 1.227(1.045–1.442) | 0.013 |
| Phase angle,° | 0.981(0.853–1.127) | 0.784 |
| MAP, mmHg | 0.973(0.955–0.991) | 0.004 |
| Use of vasopressor,& | 3.195(1.723–5.925) | <0.001 |
| SOFA score | 1.232(1.126–1.347) | <0.001 |
| APACH II | 1.081(1.032–1.133) | 0.001 |
| SAPS II | 1.011(0.996–1.026) | 0.161 |
| CVVHDF initiation time, day | 1.046(1.007–1.088) | 0.022 |
| CVVHDF dose, mL/kg/hr (actually delivered) | 0.988(0.956–1.022) | 0.487 |
| WBC,/uL | 1.006(0.975–1.038) | 0.691 |
| Hb, g/dL | 1.009(0.963–1.057) | 0.706 |
| Total protein, g/dL | 0.462(0.328–0.652) | <0.001 |
| Albumin, g/dL | 0.270(0.158–0.462) | <0.001 |
| pH, mmHg | 0.114(0.012–1.080) | 0.058 |
| BUN, mg/dL | 0.998(0.989–1.007) | 0.666 |
| Creatinine, mg/dL | 0.852(0.757–0.959) | 0.008 |
| Na, mmol/L | 1.019(0.983–1.056) | 0.312 |
| K, mmol/L | 0.854(0.663–1.101) | 0.225 |
| PT, INR | 3.084(1.680–5.662) | <0.001 |
Abbreviations: BMI, body mass index; ECW, extracelluar water; TBW, total body water; ICW, intracellular water, MAP, mean arterial pressure; SOFA, sequential organ failure assessment; CVVHDF, continuous veno-venous hemodiafiltration; BUN, blood urea nitrogen; Na, sodium; K, potassium; PT, prothrombin time.
Binary logistic regression analysis results predicting in hospital mortality in patients with AKI requiring CVVHDF therapy.
| Model I | OR | P-value |
|---|---|---|
| TBW/H2, L/m2 | 1.312(1.009–1.705) | 0.043 |
| SOFA score | 1.130(0.995–1.282) | 0.059 |
| CVVHDF initiation time,day | 1.036(0.993–1.080) | 0.098 |
| Albumin, g/dL | 0.564(0.346–0.919) | 0.022 |
In the multivariable analysis age, BMI, the presence of sepsis, TBW/H2, SOFA score, actual CVVHDF dose, CVVHDF initiation time, PT and serum albumin levels were adjusted. Abbreviations: CVVHDF, continuous veno-venous hemodiafiltration; TBW, total body water; H2, height squared; SOFA, organ failure assessment; BMI, body mass index; PT, prothrombin time.
Binary logistic regression analysis results predicting in hospital mortality in patients with AKI requiring CVVHDF therapy.
| Model II | Model III | |||
|---|---|---|---|---|
| ICW/H2, L/m2 | 1.561(1.012–2.408) | 0.044 | ||
| ECW/H2, L/m2 | 1.686(0.939–3.027) | 0.080 | ||
| SOFA score | 1.102(0.959–1.266) | 0.171 | 1.132(0.997–1.285) | 0.056 |
| CRRT initiation time, day | 1.038(0.995–1.083) | 0.086 | 1.030(0.990–1.071) | 0.144 |
| Albumin, g/dL | 0.559(0.343–0.912) | 0.020 | 0.546(0.327–0.912) | 0.021 |
In the multivariable analyses of Model II, age, BMI, the presence of sepsis, ICW/H2, sofa score, actual CVVHDF dose, CVVHDF initiation time, PT and serum albumin levels were adjusted. Model III, ICW/H2 was replaced to the ECW/H2. Abbreviations: CVVHDF, continuous veno-venous hemodiafiltration; BMI, body mass index; ICW, intracellular water; ECW, extracellular water; H2, height square; SOFA, organ failure assessment; CVVHDF, continuous veno-venous hemodiafiltration; BMI, body mass index; PT, prothrombin time.
Underlying conditions of septic AKI.
| Pneumonia | 50.6(43/85) |
| Colitis | 10.6(9/85) |
| Panperitonitis | 8.2(7/85) |
| Soft tissue infection | 8.2(7/85) |
| Acute pyelonephritis | 7.1(6/85) |
| Biliary sepsis | 7.1(6/85) |
| Catheter infection | 3.5(3/85) |
| Meningitis | 3.5(3/85) |
| Pancreatitis | 1.2(1/85) |
Foot note: AKI; acute kidney injury.
Predictors of ICU mortality in patients with septic AKI undergoing CVVHDF.
| Model I | Model II | Model III | ||||
|---|---|---|---|---|---|---|
| TBW/H2, L/m2 | 1.256(1.006–1.569) | 0.044 | ||||
| ICW/H2, L/m2 | 1.476(1.024–2.126) | 0.037 | ||||
| ECW/H2, L/m2 | 1.414(0.8446–2.364) | 0.186 | ||||
| CVVHDF initiation, day | 1.038(1.001–1.077) | 0.045 | 1.041(1.002–1.081) | 0.038 | 1.032(0.996–1.070) | 0.084 |
| Albumin, g/dL | 0.241 (0.111–0.521) | 0.001 | 0.232(0.107–0.506) | 0.001 | 0.287(0.130–0.635) | 0.002 |
In the multivariable analysis of Model I, age, BMI, TBW/H2, SOFA score, actual CVVHDF dose, CVVHDF initiation time, PT and serum albumin levels were adjusted. Model II, TBW/H2 was replaced to the ICW/H2. Model III, TBW/H2 was replaced to the ECW/H2. Abbreviations: BMI, bodoy mass index; TBW, total body water; ICW, intracellular water; ECW, extracellular water; H2, height squared; CVVHDF, continuous veno-venous hemodiafiltration; BMI, body mass index; PT, prothrombin time.